3. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Vertex Pharmaceuticals is one of the strongest examples of a biotech company that already made the difficult leap from scientific promise to commercial dominance. It is best known for its cystic fibrosis franchise, but the bigger story in 2026 is diversification. Investors are watching whether Vertex can move beyond cystic fibrosis and build new growth engines in sickle cell disease, beta thalassemia, acute pain, and nephrology. That makes Vertex one of the more serious biotech stocks to watch now, especially for investors who want a company with both commercial strength and pipeline expansion.
The May 2026 biotech watchlist highlighted Vertex’s cystic fibrosis therapies, including TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO. These products have made Vertex one of the most important players in the cystic fibrosis market. But the company is no longer relying only on that core franchise. Its newer growth areas include CASGEVY, a gene-editing therapy for sickle cell disease and beta thalassemia, and JOURNAVX, a non-opioid treatment for acute pain. That transition is important because investors want to see whether Vertex can transform from a cystic fibrosis powerhouse into a broader biotech platform.
Vertex reported first-quarter 2026 total revenue of $2.99 billion, up 8% from the first quarter of 2025. U.S. revenue increased 7% to $1.78 billion, helped by strong cystic fibrosis patient demand, new initiations of ALYFTREK, higher realized net prices in cystic fibrosis, and contributions from CASGEVY and JOURNAVX. Revenue outside the United States increased 9% to $1.21 billion, supported by cystic fibrosis performance across multiple geographies, ALYFTREK uptake, increased CASGEVY revenue, and favorable foreign exchange.
CEO Reshma Kewalramani said, “Vertex is off to a strong start in 2026,” citing leadership in cystic fibrosis, growth in sickle cell disease, beta thalassemia, and acute pain, plus rapid pipeline progress. She added that CASGEVY and JOURNAVX delivered more than 25 percent of our growth this quarter, which is a very important detail because it shows that Vertex’s non-cystic fibrosis products are starting to contribute meaningfully. She also said Vertex is building its fourth franchise in nephrology, positioning the company to deliver long-term value.
The company reiterated full-year 2026 revenue guidance of $12.95 billion to $13.1 billion, including expectations for continued growth in cystic fibrosis and $500 million or more in revenue from non-CF products. That number matters because Wall Street has been waiting for proof that Vertex can grow outside its legacy franchise. The company also ended the quarter with $13.0 billion in cash, cash equivalents, and total marketable securities, giving it a strong balance sheet to fund research, acquisitions, and commercial expansion.
For investors searching for best biotech stocks to buy now, cystic fibrosis stocks, gene editing stocks, rare disease stocks, and profitable biotech stocks, Vertex remains one of the cleaner stories in the sector. It has revenue, profit, cash, market leadership, and a pipeline that is no longer limited to one disease area. The risk is that expectations are high, and newer launches such as CASGEVY and JOURNAVX must continue proving themselves commercially. But compared with many biotech names, Vertex has the financial strength and scientific depth to stay on the radar of long-term healthcare investors.
Click next to see the following stock...
